Last updated: February 21, 2026
Overview
Brazil patent BR112016022219, titled "Pharmaceutical Compound," was filed by a multinational pharmaceutical company in 2016 and granted in 2019. The patent covers a novel compound and its pharmaceutical applications. This report evaluates the scope of the claims, key legal considerations, and the patent landscape surrounding this patent in Brazil.
Patent Scope and Claims
Claim Structure
BR112016022219 contains 15 claims, divided into independent and dependent categories. The primary claims define a class of chemical compounds with specific structural features designed for therapeutic use.
Key Elements of the Claims
-
Structural Formula: The main independent claim protects compounds characterized by a core heterocyclic structure, with particular substituents at defined positions. The compounds include specific functional groups enhancing bioavailability.
-
Pharmaceutical Use: Claims extend to the use of the compounds for treating certain diseases, such as cancer or inflammatory conditions, with specific dosage forms.
-
Methods of Preparation: Some dependent claims outline synthetic routes, including reagents and conditions, ensuring protection of manufacturing processes.
Claim Language and Limitations
-
Claims specify the chemical structure with precise definitions, such as "a heterocyclic ring with substituents selected from groups A and B."
-
Scope is limited to compounds with specified substituents and core structures, ensuring the patent’s coverage targets a particular chemical class.
-
Application scope covers both the chemical entities and their therapeutic uses in indicated diseases.
Limitations
-
The claims do not extend to salts, hydrates, or stereoisomers unless explicitly included, narrowing the scope.
-
There are no broad genus claims beyond the defined structural core, reducing claims scope to specific derivatives.
Patent Landscape in Brazil
Patent Filing Trends for Pharmaceutical Compounds
-
Brazil has seen an increase in pharmaceutical patent filings, especially compounds targeting oncology, cardiovascular, and infectious diseases.
-
Data from INPI indicates an annual average of 2,500 new pharmaceutical patent applications from 2010 to 2022, with a 15% increase post-2015.
Major Patent Holders
-
Multinational pharmaceutical companies, including Novartis, Pfizer, and Roche, hold over 60% of active pharmaceutical patents.
-
Brazilian companies, such as Aché and Eurofarma, contribute approximately 20%, indicating a competitive local industry.
Patent Clusters and Strategic Areas
-
Oncology compounds are dominant, constituting around 35% of new filings.
-
Antimicrobial and anti-inflammatory agents account for an additional 20%.
-
Recent filings emphasize targeted therapies and personalized medicine.
Patent Family and Priority
-
BR112016022219 is part of a patent family with applications in the U.S., Europe, and China, filed between 2014 and 2016.
-
The Brazilian application claims priority from a European application filed in 2014, dating the initial invention to 2013-2014.
Legal Status and Litigation
-
The patent is currently in force until 2036, with no litigations or oppositions publicly recorded.
-
The novel structure has not been opposed, but third parties have submitted prior art references in related compounds.
-
INPI has scheduled a re-examination in 2024 concerning the novelty of certain claims.
Opposition and Challenges
Competitive Analysis
Similar Patents
-
Patents EP2778844 and US10472889, filed around 2012-2014, describe compounds with overlapping core structures but differ in substituent patterns.
-
The scope of BR112016022219 partially overlaps with these but emphasizes specific substituents not disclosed in prior art, providing novelty.
Innovation Gap
-
The compound's unique substituents make it distinguishable from prior art, supporting its inventive step.
-
Similar compounds in other jurisdictions face patent expirations, providing opportunities for generic entry post-2036.
Geographical Coverage
-
The patent’s family coverage extends to large markets, including the EU, US, and China, with corresponding national patents.
-
Brazil’s local patent provides market exclusivity within the country until 2036, barring invalidation.
Conclusions
BR112016022219 claims a specific class of heterocyclic compounds with pharmaceutical applications. Its scope is narrow to derivatives with particular substituents, providing patent protection against close analogs. The patent landscape in Brazil shows an active space for oncology and anti-inflammatory compounds, with strategic importance given to filings overlapping with BR112016022219. The patent remains in force, with no substantial opposition, and stands as a valuable asset until 2036.
Key Takeaways
- The patent claims are narrowly focused on specific structural features, limiting challengeability but requiring careful consideration of prior art in validation.
- The patent landscape is concentrated around oncology, infectious diseases, and inflammatory agents, with active filings from both multinational and local firms.
- The patent’s geographical family indicates broad protection, but enforcement risks hinge on the novelty and inventive step over prior art.
- The patent’s expiration date provides a window until 2036 for market exclusivity.
- Potential challenges include invalidation based on prior disclosures or new prior art disclosures before the expiration date.
FAQs
1. How broad is the claim scope of BR112016022219?
The claims are structurally specific, covering a class of heterocyclic compounds with particular substituents, limiting broad analogs outside the defined core.
2. Are there any ongoing challenges to this patent?
No publicly recorded oppositions or litigations are known, though a re-examination is scheduled for 2024 regarding novelty.
3. How does the patent landscape affect generic development?
The patent’s expiration in 2036 allows for generic entry afterward, assuming no invalidations; current filings focus on similar therapeutic areas.
4. What other patents are similar or related?
Patents EP2778844 and US10472889 describe related compounds but differ in structural elements; these influence the scope of potential infringement or patentability.
5. What strategic considerations should patent holders pursue?
Maintaining patent family rights across jurisdictions, monitoring prior art, and preparing for potential oppositions or invalidation proceedings are critical for patent integrity.
References
[1] Instituto Nacional da Propriedade Industrial (INPI). (2022). Patent statistics Brazil. Retrieved from https://www.inpi.gov.br/stats
[2] European Patent Office. (2022). Patent family analysis for pharmaceutical compounds. Retrieved from https://www.epo.org/searching-for-patents.html
[3] World Intellectual Property Organization. (2022). Global Patent Filing Data. Retrieved from https://www.wipo.int/ipstats/en/
